Effects of Bevacizumab Combined with GP Chemotherapy on Tumor Markers and Immune Function in Non-Small Cell Lung Cancer Patients
Objective To explore the effect of bevacizumab combined with gemcitabine+cisplatin(GP)chemotherapy on non-small cell lung cancer(NSCLC)patients.Methods Clinical data of eighty-two patients with NSCLC admitted to Shouguang People's Hospital from March 2021 to March 2023 were retrospectively analyzed,and they were divided into a GP group(n=40)and a combined group(n=42)according to different treatment regimens.The GP group received GP chemotherapy and the combined group received bevacizumab combined GP chemotherapy.The disease control rate,tumor markers,immune function and toxic and side effects of the two groups were compared.Results The disease control rate of the combined group was 76.19%,higher than 57.50%of the GP group,the difference was statistically significant(P＜0.05);after treatment,the levels of carcinoembryonic antigen and serum carbohydrate antigen 125 in 2 groups were lower than before treatment,and the combined group was lower than the GP group,the differences were statistically significant(P＜0.05);after treatment,the levels of immunoglobulin A,M and G in the combination group were higher than those in the GP group,the differences between groups were statistically significant(P＜0.05);there was no significant difference in the incidence of thrombocytopenia,gastr-ointestinal reaction,leukopenia and liver and kidney damage between the two groups.Conclusion NSCLC patients treated with bevacizumab combined with GP chemotherapy can effectively alleviate the condition,improve immune function,and have relatively mild toxic side effects.
Non-small cell lung cancerBevacizumabGP chemotherapyTumor markersImmune function
NETL
NSTL
万方数据
